

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number

WO 03/101467 A1

(51) International Patent Classification⁷: A61K 31/7076.
31/7068, 47/38, A61P 31/14, 31/18

(74) Agents: LEVY, David, J et al.: GlaxoSmithKline, Corporate Intellectual Property Department, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

(21) International Application Number: PCT/US03/17347

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date: 3 June 2003 (03.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/385,717 4 June 2002 (04.06.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).

(72) Inventors: and

(75) Inventors/Applicants (*for US only*): CURRIE, Robin [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US). GOODSON, Gary, Wayne [US/US]; c/o GlaxoSmithKline, Five Moore Drive, PO Box 13398, Research Triangle Park, NC 27709 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ABACAVIR AND LAMIVUDINE

(57) Abstract: A pharmaceutical composition comprising (1S, cis)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol and (2R, cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one, in an amount which achieves antiviral efficacy, a process for the preparation of such a composition, and a method of inhibiting human immunodeficiency virus (HIV) which comprises administering such a composition to an HIV infected patient is disclosed.

Express Mail Label No.
EV 332063787 US

BEST AVAILABLE COPY

WO 03/101467 A1